XORTX THERAPEUTICS INC (XRTX)

Company Profile

XORTX Therapeutics Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Calgary, Alberta and currently employs 3 full-time employees. The company went IPO on 2015-09-30. XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The firm develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. The company is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The firm has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The firm's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

Company Info

XORTX THERAPEUTICS INC

3710 - 33rd Street NW

Calgary ALBERTA

P: 14034557727

Employees: 3

Website: https://www.xortx.com/